期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 81, 期 2, 页码 170-177出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.clpt.6100045
关键词
-
It has been almost 3 years since the launch of the FDA critical path initiative following the publication of the paper Innovation or Stagnation: Challenges and Opportunities on the Critical Path of New Medical Product Development. The initiative was intended to create an urgency with the drug development enterprise to address the so-called productivity problem in modern drug development. Clinical pharmacologists are strategically aligned with solutions designed to reduce late phase clinical trial failures to show adequate efficacy and/or safety. This article reviews some of the ways that clinical pharmacologists can lead and implement change in the drug development process. It includes a discussion of model-based, semi-mechanistic drug development, drug/disease models that facilitate informed clinical trial designs and optimal dosing, the qualification process and criteria for new biomarkers and surrogate endpoints, approaches to streamlining clinical trials and new types of interaction between industry and FDA such as the end-of-phase 2A and voluntary genomic data submission meetings respectively.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据